异基因造血干细胞移植治疗儿童慢性粒细胞性白血病的疗效分析

doi:10.7499/j.issn.1008-8830.2013.01.006

摘要
图/表
参考文献(27)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (961 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的：研究异基因造血干细胞移植（allogeneic hematopoietic stem cell transplantation, allo-HSCT）治疗儿童慢性粒细胞性白血病（chronic myelogenous leukemia, CML）的治疗效果，寻找可能的影响因素，以期改善患者预后。方法：对接受allo-HSCT治疗的20例儿童CML患者，分别从年龄、性别、诊断至移植间隔时间、供受体HLA配型相合情况、移植时患儿疾病状态以及急慢性移植物抗宿主病（gost-v-host disease, GVHD）等多种因素进行疗效分析。结果：截止至随访日期，20例患者中，13例无病存活，7例死亡，其中4例死于急性重度GVHD，2例死于慢性GVHD及其并发症，1例死于移植后复发，3年总无病生存率为（64.6±1.1%）。单因素分析显示年龄是影响儿童CML治疗预后最重要的因素之一（P0.05）。多因素logistic回归分析也进一步证明仅年龄是影响预后的因素（P<0.01）。各种严重急慢性 GVHD是引起患者死亡最重要的原因。选择10位点全相合的供体进行移植治疗预后好。结论：allo-HSCT能有效治疗儿童CML，对于年龄≥10岁的CML患儿宜早期行allo-HSCT移植治疗，且尽可能选择10位点全相合的供体进行移植，积极防治GVHD，改善CML患儿移植治疗后的转归。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	江华
	胡文婷
	陈静
	罗长缨
	王坚敏
	周敏
	叶启东
	汤燕静
	罗成娟

关键词 ：慢性粒细胞性白血病, 异基因造血干细胞移植, 移植物抗宿主病, 儿童

Abstract：OBJECTIVE: To investigate the therapeutic efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with chronic myelogenous leukemia (CML), and to analyze the possible prognostic factors.MethodsThe clinical data of 20 children with CML who had received allo-HSCT was analyzed retrospectively to investigate possible prognostic factors, including age, sex, interval between diagnosis and transplantation, HLA matching between donors and recipients, illness status on transplantation and acute and chronic graft-versus-host disease (GVHD).ResultsAt the end of follow-up, 13 of the 20 treated children had disease-free survival (DFS) and the rest (7 cases) died. Four died of severe acute GVHD, two of chronic GVHD and its complications, and one of relapse after transplantation. The three-year DFS was (64.6±1.1%). As shown by the univariate analysis, age was the most important prognostic factor in children with CML who had received allo-HSCT (P0.05). The multivariate logistic regression analysis also confirmed age as the only prognostic factor (P<0.01). Severe acute and/or chronic GVHD was the most important cause of patient death. 10/10 HLA-matched donors could improve the transplantation outcome.ConclusionsAllo-HSCT is an effective treatment for children with CML. To improve the prognosis and treatment outcome, children with CML aged over 10 years should receive allo-HSCT as early as possible. 10/10 HLA-matched donors are preferred in allo-HSCT and GVHD should be prevented.

Key words： Chronic myelogenous leukemia Allogeneic hematopoietic stem cell transplantation Graft-versus-host disease Child

引用本文:

江华,胡文婷,陈静等. 异基因造血干细胞移植治疗儿童慢性粒细胞性白血病的疗效分析[J]. 中国当代儿科杂志, 2013, 15(1): 19-24.

JIANG Hua,HU Wen-Ting,CHEN Jing et al. Therapeutic efficacy of allogeneic hematopoietic stem cell transplantation in children with chronic myelogenous leukemia[J]. CJCP, 2013, 15(1): 19-24.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2013.01.006 或 http://www.zgddek.com/CN/Y2013/V15/I1/19

	［1］Castro-Malaspina H, Schaison G, Briere J, Passe S, Briere J, Pasquier A, et al. Philadelphia chromosome-positive chronic myelocytic leukemia in children. Survival and prognostic factors［J］. Cancer, 1983, 52(4): 721-727.
	［6］Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading［J］. Bone Marrow Transplant, 1995, 15(6): 825-828.
	［2］Altman AJ. Chronic leukemias of childhood［J］. Pediatr Clin North Am, 1988, 35(4): 765-787.
	［7］Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report［J］. Biol Blood Marrow Transplant, 2005, 11(12): 945-956.
	［3］Lee JW, Chung NG. The treatment of pediatric chronic myelogenous leukemia in the imatinib era［J］. Korean J Pediatr, 2011, 54(3): 111-116.
	［8］Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, et al. Choice of pretreatment treatment and timing of transplants for chronic myelogenous leukemia in chronic phase［J］. Blood, 1993, 82(7): 2235-2238.
	［4］Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia［J］. Semin Hematol, 1988, 25(1): 49-61.
	［9］Gratwohl A, Hermans J, Apperley J, Arcese W, Bacigalupo A, Bandini G, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia［J］. Blood, 1995, 86(2): 813-818.
	［5］韩伟，陆道培，黄晓军，刘开彦，陈欢，许兰平，等.HLA配型不合造血干细胞移植GIAC方案100例临床分析［J］. 中华血液学杂志，2004，25（8）：453-457.
	［10］Sharathkumar A, Thornley I, Saunders EF, Calderwood S, Freedman MH, Doyle J. Allogenic bone marrow transplantation in children with chronic myelogenous leukemia［J］. J Pediatr Hematol Oncol, 2002, 24(3): 215-219.
	［6］Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading［J］. Bone Marrow Transplant, 1995, 15(6): 825-828.
	［11］Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, et al. Marrow transplantation for the treatment of chonic myelogenous leukemia［J］. Ann Intern Med, 1986, 104(2): 155-163.
	［7］Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report［J］. Biol Blood Marrow Transplant, 2005, 11(12): 945-956.
	［12］Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, longterm data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) ［J］. Haematologica, 2006, 91(4): 513-521.
	［8］Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, et al. Choice of pretreatment treatment and timing of transplants for chronic myelogenous leukemia in chronic phase［J］. Blood, 1993, 82(7): 2235-2238.
	［13］Unal S, Fidan G, Tavil B, Cetin M, Cetinkaya DU. Allogeneic hematopoietic stem cell transplantation in pediatric chronic myelogenous leukemia cases: Hacettepe experience［J］. Pediatr Transplant, 2007, 11(6): 645-649.
	［9］Gratwohl A, Hermans J, Apperley J, Arcese W, Bacigalupo A, Bandini G, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia［J］. Blood, 1995, 86(2): 813-818.
	［10］Sharathkumar A, Thornley I, Saunders EF, Calderwood S, Freedman MH, Doyle J. Allogenic bone marrow transplantation in children with chronic myelogenous leukemia［J］. J Pediatr Hematol Oncol, 2002, 24(3): 215-219.
	［14］Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A, et al. Stem cell transplantation for chronic myeloid leukemia in children［J］. Blood, 2003, 102(4): 1224-1231.
	［11］Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, et al. Marrow transplantation for the treatment of chonic myelogenous leukemia［J］. Ann Intern Med, 1986, 104(2): 155-163.
	［15］Rubio MT, Moreira-Teixeira L, Bachy E, Bouillié M, Milpied P, Coman T,et al.Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival［J］. Blood, 2012, 120(10): 2144-2154.
	［16］Suttorp M, Yaniv I, Schultz KR.Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?［J］. Biol Blood Marrow Transplant, 2011, 17(1 Suppl): S115-S122.
	［12］Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, longterm data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) ［J］. Haematologica, 2006, 91(4): 513-521.
	［13］Unal S, Fidan G, Tavil B, Cetin M, Cetinkaya DU. Allogeneic hematopoietic stem cell transplantation in pediatric chronic myelogenous leukemia cases: Hacettepe experience［J］. Pediatr Transplant, 2007, 11(6): 645-649.
	［14］Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A, et al. Stem cell transplantation for chronic myeloid leukemia in children［J］. Blood, 2003, 102(4): 1224-1231.
	［15］Rubio MT, Moreira-Teixeira L, Bachy E, Bouillié M, Milpied P, Coman T,et al.Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival［J］. Blood, 2012, 120(10): 2144-2154.
	［16］Suttorp M, Yaniv I, Schultz KR.Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?［J］. Biol Blood Marrow Transplant, 2011, 17(1 Suppl): S115-S122.